Although formal data on pharmacokinetic or pharmacodynamic interactions between recreational drugs and antiretroviral agents are lacking, information regarding potentially toxic interactions can be theorized or sometimes conclusions may be drawn from case studies and cohort observational studies.
However, the risk of coadministering party drugs and antiretrovirals should not be overestimated. The major risk for a drug-drug interaction is when using ritonavir-boosting or cobicistat-boosting agents, and maybe some nonnucleoside reverse transcriptase inhibitors. Knowledge of the metabolic pathways of 'party drugs' may help in advising patients on which illicit substances have a high potential for drug-drug interactions, as this is not the case for all.
Via: http://ht.ly/SmB1Z
By: Bracchi M1, Stuart D, Castles R, Khoo S, Back D, Boffito M.
- 1aSt Stephen's AIDS Trust bDean Street Clinic, Chelsea and Westminster Hospital cJonathan Mann Clinic, Homerton Hospital dUniversity of Liverpool, Liverpool eImperial College, London, UK.
More at: https://twitter.com/hiv_insight
No comments:
Post a Comment